Arkolith/Insider Trading/OTLK/Form 4

Sukhtian Ghiath M.

Director, 10% OwnerOutlook Therapeutics, Inc. (OTLK) · full profile →Form 4 · filed Jun 1, 2026
Net Buying
Open-Market Buys
$5.0M
Open-Market Sells
$0
Net Open-Market Flow
$5.0M
Transactions
7
1 non-derivative · 6 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 28, 2026Buy(P)8.5M$0.59$5.0M22.1M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 28, 2026Expiration(H)3.5M——0
May 28, 2026Buy(P)3.5M——3.5M
May 28, 2026Expiration(H)3.5M——0
May 28, 2026Buy(P)3.5M——3.5M
May 28, 2026Expiration(H)8.6M——0
May 28, 2026Buy(P)8.6M——8.6M

Transaction Codes

P
Open-market purchase
H
See SEC Form 4 code table

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000899140-26-000620) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for Outlook Therapeutics, Inc.

Build

Ask your agent about OTLK insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0000899140-26-000620"
Ask your agent
Use Arkolith to summarize insider buying and selling at Outlook Therapeutics, Inc.
over the last 90 days and cite the filings.